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Abstract 
Background: The purpose of this study is to investigate whether histogram analysis of apparent 
diffusion coefficient (ADC) can serve as a prognostic biomarker for esophageal squamous cell 
carcinoma (ESCC). 
Methods: This retrospective study enrolled 116 patients with ESCC who received curative 
surgery from 2006 to 2015 (including 70 patients who received neoadjuvant chemotherapy). 
Diffusion-weighted magnetic resonance imaging (DWI) was performed before the treatment. The 
ADC maps were generated by DWIs at b=0 and 1000 (s/mm2), and analyzed to obtain ADC 
histogram-derived parameters (ADC mean, kurtosis, and skewness) of the primary tumor. 
Associations of these parameters with pathological features were analyzed, and Cox regression 
and Kaplan-Meier analysis were performed to compare these parameters with recurrence free 
survival (RFS) and disease specific survival (DSS). 
Results: Kurtosis was significantly higher in tumors with lymphatic invasion (p=0.005) with 
respect to the associations with pathological features. In univariate Cox regression analysis, 
tumor depth, lymph node status, ADC mean, and kurtosis were significantly correlated with RFS 
(p=0.047, p<0.001, p=0.037, p<0.001, respectively), while lymph node status and kurtosis were 
also correlated with DSS (p=0.002, p=0.017, respectively). Furthermore, multivariable analysis 
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demonstrated that kurtosis was the independent prognostic factor for both RFS and DSS 
(p<0.001, p=0.015, respectively). In Kaplan-Meier analysis, patients with higher kurtosis tumors 
(>3.24) showed a significantly worse RFS and DFS (p<0.001, p=0.006, respectively). 
Conclusions: Histogram analysis of ADC may serve as a useful biomarker for ESCC, reflecting 
pathological features and prognosis. 
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Introduction 
Esophageal squamous cell carcinoma (ESCC) is an extremely aggressive malignant tumor with a 
poor prognosis. Despite recent advances in diagnosis and treatment, the recurrence rate after 
radical resection has been reported to be approximately 50%. Additionally, most cases of 
recurrence occur within two years after surgery.1,2 Therefore, developing biomarkers that can 
predict the clinical outcomes is highly desirable to identify the patients who are in the need for 
more effective multidisciplinary treatments. 
It is widely known that malignant tumors exhibit an abnormal microenvironment that is 
characterized by high cellularity and unusual interstitial structure, which can considerably affect 
the treatment response and survival.3 These biological features are usually investigated in the 
fields of cell and molecular biology, but various imaging techniques have been proposed for the 
noninvasive assessment of these features to employ them as the useful biomarkers for treatment 
and prognosis of cancer. Diffusion-weighted magnetic resonance imaging (DWI) is one of 
imaging techniques that can assess the biological features of malignancies. The usage of DWI 
has increased over the years. Additionally, its potential as a biomarker for cancer treatment has 
been reported.4 The apparent diffusion coefficient (ADC), which can be calculated from DWI, is 
considered to indirectly measure the biological properties, such as cellularity and stromal 
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characteristics, which could affect water diffusion.5 Besides, the analysis of texture within tumor 
on medical images, such as computed tomography (CT) and MRI, which may reflect structural 
abnormality and heterogeneity in the tumor, has recently been reported to be used as a biomarker 
for cancer treatment.1,6 Histogram analysis is one of the texture analyses, which could be a 
potential biomarker for the prediction of treatment response and survival in malignancies.7,8 It 
has been reported that histogram analysis of ADC could help to further the prediction of 
histological features, TNM staging, aggressiveness, therapeutic response and survival in various 
malignancies, such as lung cancer,9 thyroid cancer,10 pancreatic cancer,11 rectal cancer,12 and 
salivary gland carcinoma.13 
However, to our knowledge, there has been no study which had demonstrated that histogram 
analysis of ADC could predict the pathological features and survival of surgically treated 
esophageal cancer. Therefore, the purpose of this study is to investigate whether ADC 
histogram-derived parameters could predict the pathological features and prognosis in the 
patients with ESCC. 
 
Materials and Methods 
Patient population 
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This study enrolled 116 patients with ESCC who were treated by curative surgery with or 
without neoadjuvant chemotherapy (NAC) at our institution between November 2006 and 
December 2015 in this retrospective study. Squamous cell carcinoma of the esophagus was 
histopathologically proven from the biopsy specimens in all these patients, who underwent MRI 
before the treatment. Based on 8th edition of the UICC TNM Classifition14, the clinical stage was 
determined by an upper endoscopic examination with tumor biopsy, barium esophagography, 
chest and abdominal CT scans, MRI, and 18F-fluorodeoxyglucose positron emission tomography 
(FDG-PET). The institutional review board at our institute (IRB number 3032) provided 
approval for our retrospective study. Due to the retrospective nature of this study, written 
informed consent for participation was not required; however, written informed consent to 
undergo surgery and imaging examinations, including CT, MRI, and FDG-PET, was obtained 
from all the patients. 
 
Treatment plan and therapeutic effect 
The standard treatment recommended by the Japan Clinical Oncology Group (JCOG) 9907 
Study for patients with clinical UICC Stage Ⅱ /Ⅲ  resectable ESCC is preoperative 
chemotherapy followed by esophagectomy with lymphadenectomy.15 The NAC consisted of 2 
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cycles of 5-fluorouracil (800 mg/m2 in a continuous infusion for five days) and cisplatin (80 
mg/m2 on day 1). All patients underwent radical esophagectomy with 3-field lymphadenectomy 
including cervical, mediastinal, and abdominal lymph node dissection.  
The criteria for the pathological response to NAC in the primary tumor were categorized as 
follows: no viable tumor cells remain in the main tumor (Grade 3), viable tumor cells remain in 
less than one-third of the tumorous area (Grade 2), viable tumor cells remain more than one-third 
of the tumorous area (Grade 1), and no evidence of effect was found (Grade 0).16 
 
Magnetic resonance imaging and analysis  
MRI examinations were performed before the treatment with a 1.5 T whole-body scanner 
(Achieva 1.5 T Nova Dual; Philips Medical, Best/Heeren, The Netherlands). T2-weighted fast 
spin echo images were obtained with the following parameters: repetition time (TR)/echo time 
(TE): 1100/110 ms; slice thickness: 4 mm; matrix size: 256 × 204; and field of view: 320×320 
mm. DWI scans were obtained by using a single-shot spin-echo type of echo-planar sequence, 
and fat signals were suppressed by using short-tau inversion recovery. The imaging parameters 
were as follows: TR/TE: 7800/65 ms; slice thickness: 4 mm; matrix size: 160×125; field of view: 
400 ×400 mm; b value: 0 and 1000 s/mm2; acquisition time: 7 min with free breathing scanning. 
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All MRI dates were transferred to a workstation (Aze Virtual Place Advanced Plus, Aze, Tokyo, 
Japan). On the axial ADC map, the regions of interest (ROI) were manually drawn with the 
exclusion of visually identified vessels and necrotic areas, while referring to the T2-weighted 
images by an investigator, who was blinded to the histopathology results. Tumor boundaries 
were traced manually on every continuous slice that contained the tumor to include the 
whole-tumor volume in the volume of interest (VOI). From the VOI data of the tumor, histogram 
parameters such as ADC mean, kurtosis, and skewness were measured (Fig.1).  
 
18F-Fluorodeoxyglucose positron emission tomography 
We obtained FDG-PET images by using a PET scanner (Advance Nxi, GE Medical Systems). 
Patients were fasted for at least four hours before the examination. A whole-body image was 
initiated 60 min after the injection of 18F-FDG (370 MBq). Images were obtained as per the 
following sequence: emission: 4 min; transmission: 2 min; thickness: 4.25 mm; matrix: 128 × 
128; and data reconstruction was performed by the ordered subset expectation maximization 
(OSEM) method. The degree of FDG uptake was quantified as the standardized uptake value 
(SUV), which was defined as the concentration of radioactivity in the tissue or lesion ((MBq)/ml 
× patient body weight (g)/injected dose (MBq)). We used SUV max that was defined as the 
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maximum value in the primary tumor. 
 
Statistical analysis 
Continuous variables were expressed as median (min-max). All statistical analyses were 
performed by JMP Pro 13.2 software (SAS Institute, Inc., Cary, NC, USA). The Mann-Whitney 
U test was used to compare ADC histogram-derived parameters and pathological features. The 
Cox proportional hazards regression model was employed for both univariate and multivariable 
analyses of survival. Relapse free survival (RFS) and disease specific survival (DFS) curves 
were drawn by using the Kaplan-Meier method, and the significance of differences between 
survival curves was analyzed by the log-rank test. A value of p of less than 0.05 were considered 
statistically significant. 
 
Results 
Patients’ characteristics 
All 116 patients underwent radical surgery with or without NAC. The surgery alone group 
consisted of 46 cases, while the NAC group consisted of 70 cases. Table 1 presents a detailed 
summary of the patients’ characteristics. The median follow-up period was 42.4 months 
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(3.1-130.8 months). 
 
Relationship between ADC histogram-derived parameters and histopathological features 
We compared ADC histogram-derived parameters and histopathological factors in the surgery 
alone group. Table 2 presents the detailed results of this comparison. ADC mean of tumors did 
not have significant correlations with any of the pathological features. Kurtosis was significantly 
higher in tumors with lymphatic invasion (p=0.005) and tended to be higher in pStage Ⅲ-Ⅳ 
patients than that in pStage Ⅰ-Ⅱ patients (p=0.07). No significant relationship of skewness with 
histopathological features was observed. 
 
Correlation between ADC histogram-derived parameters and survival 
Table 3 presents the results of Cox regression analyses that were used to investigate the effects of 
ADC histogram-derived parameters on the survival outcomes in the whole group. ADC mean, 
kurtosis, pathological tumor depth status (pT), and pathological lymph node status (pN) were all 
significant for RFS (p=0.037, <0.001, 0.047, and <0.001, respectively). Additionally, kurtosis 
and pN status were significant for DSS (p=0.017 and 0.002, respectively) at the univariate 
analysis. In the multivariable analysis, ADC mean and kurtosis were independent prognostic 
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factors for RFS (p=0.042, <0.001, respectively), while kurtosis was an independent prognostic 
factors for DSS (p=0.015). For Kaplan-Meier analysis, patients were divided into two groups, 
high kurtosis group >3.24 (n=58) and low kurtosis group ≤3.24 (n= 58), based on the median 
value of kurtosis. Patients with higher kurtosis tumors showed significantly worse five-year RFS 
(70.0% vs 33.2%, p<0.001) and five-year DSS (75.6% vs 47.2%, p=0.006) (Figure 2). 
 
Subgroup analysis for survival in the positive lymph node group 
Despite an extremely poor prognosis of positive lymph node ESCCs, it is true that some of them 
will not relapse within five years after surgery. In fact, there were significant differences between 
patients with pN + and pN - in five-year RFS (82.7% vs 37.5%, p<0.001) and five-year DSS 
(88.0% vs 50.5%, p<0.001) in this cohort. Thus, subgroup analysis of patients with ESCC having 
pathologically positive lymph node was performed to investigate whether ADC histogram 
analysis would enable the risk stratification of patients with positive lymph node ESCC. This 
cohort involved 79 patients with positive lymph node ESCCs. In Kaplan-Meier analysis, patients 
with lower kurtosis tumors (≤3.24) showed a better five-year RFS (64.4% vs 9.3%, p<0.001) and 
five-year DSS (67.7% vs 31.8%, p=0.005) (Figure 3). Thus, patients with lower kurtosis tumors 
might be expected a better prognosis, even though they have lymph node metastasis. 
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Discussion 
Our study indicated that histogram analysis of ADC could serve as a potential biomarker for the 
prediction of tumor aggressiveness and survival in esophageal cancer. We found that kurtosis was 
significantly correlated with lymphatic invasion, which was the most useful parameter for the 
prediction of survival in ESCC. 
DWI has been considered as an imaging biomarker for the detection and characterization of 
cancers as well as prediction and monitoring of the response to cancer treatment.4 The commonly 
used mean ADC disregards the heterogenous structure of the tumor, which is an essential 
biological characteristic of malignancies, whereas histogram approaches are adapted to evaluate 
this tumor heterogeneity.7 Therefore, we used whole-tumor histogram analysis of ADC for the 
assessment of structural abnormality of the entire tumor. Furthermore, ADC histogram analysis 
has been reported to be a reproducible technique,17 and we had already reported a high 
reproducibility of whole-tumor histogram analysis of ADC in the other study of esophageal 
cancer.18 
In this study, we found that higher kurtosis of the tumor was associated with lymphatic invasion. 
This result was consistent with a previous study about lung cancer.9 Various studies showed that 
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ADC histogram analysis could assess the structural abnormality of the tumor, and ADC kurtosis 
might serve as a potential biomarker for the evaluation of heterogeneity, cell differentiation, and 
aggressive behavior of the tumor.7,19 ADC kurtosis reflects the peakedness and heaviness of the 
tail of the distribution of ADC values, and higher kurtosis indicates a shaper peak and wider tails. 
It is speculated that higher ADC kurtosis represents the microstructural and functional 
heterogeneity of the tumor,11,17,20 which has been reported to be associated with poor prognosis 
in malignancies.6 For example, tumors with higher kurtosis was associated with poorly 
differentiation in breast cancer,19 head and neck cancer23 and gastric cancer.21 In pancreatic 
neuroendocrine tumor,11 higher kurtosis of the tumor had a correlation with malignant behavior, 
such as vascular involvement, nodal and hepatic metastases. Malignant tumors showed higher 
kurtosis than benign tumors in orbital tumor22 and urinary bladder tumor.20 Therefore, we 
speculated that higher ADC kurtosis of ESCC tumor might be attributed to the heterogeneity and 
structural abnormalities of the tumor and has a more aggressive malignant potential. 
Additionally, this study found that higher ADC mean and higher kurtosis of the tumor indicated a 
significantly worse prognosis. This finding was similar to a previous study which reported that 
higher kurtosis of salivary gland carcinoma was associated with poor survival.13 It was reported 
that ADC was positively related to the tumor stroma ratio in several types of cancers24,25 and 
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associated with survival in mass-forming intrahepatic cholangiocarcinoma.26 In ESCCs, several 
studies have recently demonstrated the clinical significance of tumor stroma in cancer 
progression. These studies reported that stroma abundance as well as stroma density and maturity 
have been related to chemotherapy resistance and prognosis.27–29 Histogram analysis of medical 
imaging has been reported to reflect the structural abnormality and heterogeneity in the 
tumor.1,7,30 Therefore, we speculated that higher ADC mean might be associated with abundant 
stroma, and higher ADC kurtosis might reflect the abnormal structure of the tumor stroma, such 
as dense or immature stroma, resulting in worse survival. However, it might be still difficult to 
explain these imaging features from the biological point of view, and further studies are needed 
to investigate how these features are associated with tumor biology. But how can we save 
patients with such high kurtosis tumors? Our previously published study suggested that 
esophageal cancers with high kurtosis tended to achieve a pathological complete response after 
chemoradiation therapy (CRT) followed by curative surgery.18 Thus, we speculated that 
pre-operative CRT rather than chemotherapy could improve the outcome of patients with high 
kurtosis tumors, and this hypothesis will be investigated in the future studies. 
Our study has several limitations. First, our study was based on single-center retrospective data, 
with a relatively smaller sample size. Furthermore, prospective investigations with larger 
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populations in multicenter are needed to strengthen the statistical power of the results. Second, 
biological investigations of histogram-derived parameters have yet to be confirmed. Future 
studies should compare these image-derived parameters with biology such as tumor stroma. 
Third, the setting of the tumor ROIs was subjective. We hope that an automatic tumor segmentation 
method with high reproducibility and reliability will be developed. 
 
Conclusions 
Our study demonstrated that higher ADC kurtosis of the ESCC tumor was associated with a poor 
prognosis. Currently, MRI is not a standard examination in the management of esophageal cancer, 
and the cost of MRI is relatively higher than other imaging modalities. However, ADC 
histogram-derived parameters would enable personalized therapy while preventing adverse 
events and providing the best treatment strategy for patients with esophageal cancer, which 
would lead to better outcomes and cost benefits. Therefore, we believe that our results could 
contribute to the selection of the optimal therapeutic strategy for patients with ESCC. 
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Figure legends 
Figure 1 
Axial magnetic resonance imaging (MRI) of an 81-year-old male with esophageal cancer. 
(a) T2-weighted image (T2WI), (b) apparent diffusion coefficient (ADC) map (b=0, 1000 s/mm2), 
regions of interests (ROIs) were manually drawn around the tumor on the axial ADC map 
referring to T2WI and each slice was assessed resulting in a volumetric measurement, and (c) 
histogram of ADC values, distribution of pixels in the volume of interest (VOI) is quantified as 
histogram parameters such as kurtosis and skewness 
 
Figure 2 
Kaplan-Meier curves of (a) relapse free survival and (b) disease specific survival according to 
kurtosis in the whole group (116 patients) 
 
Figure 3 
Kaplan-Meier curves of (a) relapse free survival and (b) disease specific survival according to 
kurtosis in the subgroup (pathological lymph node positive: pN +, 79 patients) 
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Table 1 
Patients’ characteristics 
 
 
 All population  
(n=116) 
Surgery alone group 
(n=46) 
Neoadjuvant chemotherapy 
group (n=70) 
Age 68 (49-84) 70 (49-84) 66 (54-77) 
Sex    
Male : Female 96 : 20 35 : 11 61 : 9 
Primary site    
Ce/Ut/Mt/Lt/Ae 3/14/40/46/13 2/5/17/18/4 1/9/23/28/9 
Pathological T status    
  T0/T1/T2/T3/T4 2/13/32/62/7 0/3/14/26/3 2/10/18/36/4 
Pathological N status    
N0/N1/N2/N3 37/32/29/18 15/13/14/4 22/19/15/14 
Pathological Stage    
0/ⅠA/ⅠB/ⅡA/ⅡB/ⅢA/ⅢB/ⅣA 2/1/11/10/18/14/41/19 0/4/6/6/4/22/4 2/1/7/4/12/10/19/15 
Pathological response    
Grade 0/1/2/3 ― ― 2/57/9/2 
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Table 2 
Relationship between ADC histogram-derived parameters and histopathological features in the surgery alone group (n=46) 
 
 
 
 
 
 
 
 
 
 
 ADC mean P Kurtosis P Skewness P 
Pathological T status       
 pT 1-2 1.29 (1.01-1.65) 
0.72 
3.16 (2.40-5.16) 
0.15 
0.075 (-0.81-0.60) 
0.06 
 pT 3-4 1.27 (0.94-1.86) 3.39 (2.55-6.66) 0.29 (-0.82-1.39) 
Pathological N status       
 pN - 1.25 (0.94-1.48) 
0.12 
2.87 (2.55-5.16) 
0.32 
0.11 (-0.81-0.55) 
0.083 
 pN + 1.29 (0.95-1.86) 3.46 (2.40-6.66) 0.31 (-0.82-1.39) 
Pathological Stage       
 pStage Ⅰ-Ⅱ 1.28 (0.89-1.62) 
0.66 
3.17 (2.03-5.16) 
0.07 
0.06 (-0.81-0.81) 
0.07 
 pStage Ⅲ-Ⅳ 1.28 (0.92-1.86) 3.36 (2.53-6.66) 0.19 (-0.88-1.39) 
Histology       
 Well or Moderately differentiated 1.29 (0.94-1.86) 
0.35 
3.36 (2.4-6.66) 
0.89 
0.20 (-0.8-1.39) 
0.71 
 Poorly differentiated 1.21 (1.01-1.59) 3.46 (2.77-3.97) 0.29 (-0.71-0.95) 
Vascular invasion       
 v - 1.12 (1.05-1.86) 
0.13 
2.96 (2.40-4.33) 
0.26 
0.20 (-0.28-0.55) 
0.69 
 v + 1.45 (0.94-1.65) 3.39 (2.55-6.66) 0.20 (-0.82-1.39) 
Lymphatic invasion       
 ly - 1.27 (0.94-1.57) 
0.30 
2.96 (2.40-5.16) 
0.005 
0.14 (-0.81-0.69) 
0.61 
 ly + 1.30 (0.95-1.86) 3.55 (2.76-6.66) 0.29 (-0.82-1.39) 
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Table 3 
Univariate and multivariable Cox regression analyses for relapse free survival (RFS) and disease specific survival (DSS) 
pT pathological T status, pN pathological N status, NAC neoadjuvant chemotherapy, HR hazard ratio, CI confidence interval 
 
 
 
 Relapse free survival (RFS)  Disease specific survival (DSS) 
Univariate Multivariable  Univariate Multivariable 
HR 95% CI P HR 95% CI P  HR 95% CI P HR 95% CI P 
pT 0-2 vs pT 3-4 1.75 1.02-3.12 0.047 1.76 0.99-3.18 0.06  1.48 0.80-2.86 0.22    
pN - vs pN + 5.54 2.57-14.4 <0.001 5.71 2.62-15.0 <0.001  5.26 2.11-17.6 0.002 5.29 2.12-17.7 0.002 
NAC vs Surgery alone 1.16 0.67-1.98 0.58     1.13 0.60-2.10 0.69    
SUV max 1.04 0.99-1.07 0.052     1.03 0.99-1.08 0.12    
ADC mean 3.92 1.08-14.0 0.037 3.45 1.02-11.1 0.042  3.04 0.70-13.0 0.14    
Kurtosis 1.81 1.33-2.39 <0.001 1.85 1.33-2.48 <0.001  1.60 1.06-2.29 0.017 1.60 1.06-2.26 0.015 
Skewness 1.83 0.89-3.72 0.10     1.37 0.60-3.10 0.46    
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